Skip to main content
Erschienen in: Clinical and Translational Oncology 2/2017

19.05.2016 | Brief Research Article

Is mucin a determinant of peritoneal dissemination of gastrointestinal cancer? Analysis of mucin depletion in two preclinical models

verfasst von: S. Masoumi-Moghaddam, A. Amini, D. L. Morris

Erschienen in: Clinical and Translational Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Mucinous gastrointestinal cancers may indicate a higher propensity for widespread peritoneal seeding than their non-mucinous counterparts. We hypothesized that mucin content of gastrointestinal cancer cells and tumors is an indicator of cell viability and a determinant of the peritoneal tumor burden and tested our hypothesis in relevant experimental models.

Methods

MKN45 and LS174T models of human gastrointestinal cancer were treated with known mucin-depleting agents in vitro and in vivo, their mucin production was evaluated with Western blot immunohistochemistry, PAS staining and ELISA, and its correlation with cell viability and peritoneal tumor burden was analyzed.

Results

A relationship was found between the viability of cancer cells and their mucin levels in vitro. In agreement, when treated animal models were categorized into low- and high-burden groups (based on the weight and number of the peritoneal nodules), tumoral mucin levels were found to be significantly higher in the latter group.

Conclusions

Tumoral mucin is apparently among the factors that dictate the pattern and extent of the peritoneal spread of gastrointestinal cancer, where it allows for enhanced dissemination and redistribution. If further tested and validated, our hypothesis could lay the basis for the development of novel mucin-targeted strategies.
Literatur
1.
Zurück zum Zitat Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95:93–6.CrossRefPubMed Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95:93–6.CrossRefPubMed
2.
Zurück zum Zitat Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbecks Arch Surg. 1999;384:576–87.CrossRefPubMed Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbecks Arch Surg. 1999;384:576–87.CrossRefPubMed
3.
Zurück zum Zitat Esquivel J. Treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2012;21:xv–xviii.CrossRefPubMed Esquivel J. Treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2012;21:xv–xviii.CrossRefPubMed
4.
Zurück zum Zitat Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol. 2011;18:e84–96.CrossRefPubMedPubMedCentral Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol. 2011;18:e84–96.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003;22:465–72.CrossRefPubMed Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003;22:465–72.CrossRefPubMed
6.
Zurück zum Zitat Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4:45–60.CrossRefPubMed Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4:45–60.CrossRefPubMed
7.
Zurück zum Zitat Jonckheere N, Skrypek N, Van Seuningen I. Mucins and tumor resistance to chemotherapeutic drugs. Biochim Biophys Acta. 2014;1846:142–51.PubMed Jonckheere N, Skrypek N, Van Seuningen I. Mucins and tumor resistance to chemotherapeutic drugs. Biochim Biophys Acta. 2014;1846:142–51.PubMed
8.
Zurück zum Zitat Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20:332–42.CrossRefPubMed Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20:332–42.CrossRefPubMed
9.
10.
Zurück zum Zitat Amini A, Masoumi-Moghaddam S, Ehteda A, Morris D. Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: significance of combination therapy. J Exp Cli Cancer Res. 2014;33:92. Amini A, Masoumi-Moghaddam S, Ehteda A, Morris D. Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: significance of combination therapy. J Exp Cli Cancer Res. 2014;33:92.
11.
Zurück zum Zitat Amini A, Masoumi-Moghaddam S, Ehteda A, Liauw W, Morris DL. Depletion of mucin in mucin-producing human gastrointestinal carcinoma: results from in vitro and in vivo studies with bromelain and N-acetylcysteine. Oncotarget. 2015;6:33329–44.PubMedPubMedCentral Amini A, Masoumi-Moghaddam S, Ehteda A, Liauw W, Morris DL. Depletion of mucin in mucin-producing human gastrointestinal carcinoma: results from in vitro and in vivo studies with bromelain and N-acetylcysteine. Oncotarget. 2015;6:33329–44.PubMedPubMedCentral
12.
Zurück zum Zitat Amini A, Masoumi-Moghaddam S and Morris DL. Utility of bromelain and N-acetylcysteine in treatment of peritoneal dissemination of gastrointestinal mucin-producing malignancies. Springer International Publishing; 2016. Amini A, Masoumi-Moghaddam S and Morris DL. Utility of bromelain and N-acetylcysteine in treatment of peritoneal dissemination of gastrointestinal mucin-producing malignancies. Springer International Publishing; 2016.
13.
Zurück zum Zitat Gum JR Jr. Mucin genes and the proteins they encode: structure, diversity, and regulation. Am J Respir Cell Mol Biol. 1992;7:557–64.CrossRefPubMed Gum JR Jr. Mucin genes and the proteins they encode: structure, diversity, and regulation. Am J Respir Cell Mol Biol. 1992;7:557–64.CrossRefPubMed
14.
Zurück zum Zitat Amini A, Masoumi-Moghaddam S and Morris DL, editors. Mucins and tumor biology. In: Utility of bromelain and N-acetylcysteine in treatment of peritoneal dissemination of gastrointestinal mucin-producing malignancies. Springer International Publishing; 2016. p. 43–57. Amini A, Masoumi-Moghaddam S and Morris DL, editors. Mucins and tumor biology. In: Utility of bromelain and N-acetylcysteine in treatment of peritoneal dissemination of gastrointestinal mucin-producing malignancies. Springer International Publishing; 2016. p. 43–57.
15.
Zurück zum Zitat Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004;23:77–99.CrossRefPubMed Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004;23:77–99.CrossRefPubMed
Metadaten
Titel
Is mucin a determinant of peritoneal dissemination of gastrointestinal cancer? Analysis of mucin depletion in two preclinical models
verfasst von
S. Masoumi-Moghaddam
A. Amini
D. L. Morris
Publikationsdatum
19.05.2016
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 2/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1519-8

Weitere Artikel der Ausgabe 2/2017

Clinical and Translational Oncology 2/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.